|
|
Profile
|
Delegates :
Shizuka Akieda |
|
Incorporated :
August 11 , 2010 |
Paid in Capital :
100 Million yen |
Employees :
22 人 |
Address :
2-27-17 Hongo, Bunkyo-ku TOKYO
〒113-0033
|
TEL/FAX :
+81-3-4455-7872 / |
URL：
http://www.cyfusebio.com/en/ |
Attachment :
|
Mission/Background :
Cyfuse utilizes its unique platform technology of three-dimensionally layered cells (Spheroid) to regenerate tissues and organs that malfunction because of disease or injury. We are aiming to contribute to save a number of patients in response to meet the unmet medical needs that were not satisfied by existing surgery or treatments. Transplantation of a cellular structure created from cells only into humans is a new treatment option as a breakthrough approach expected to be safe with high therapeutic effects. We have been promoting the development for the regeneration of various tissues and organs, such as bone and cartilage, blood vessels, and nerves, by using its unique platform technology. Also, we are putting the technology into practical use as a drag screening tool to evaluate the efficacy, toxicity, and metabolism of new drugs. The pipelines of Cyfuse are based on unmet medical needs and the cell products created by platform technology is expected to be used in actual medical settings in the future. |
|
Technology & Business
|
The company’s technology uses a fine needle array to skewer cellular aggregates (0.5mm diameter), which are then stacked three dimensionally. Once the cellular aggregates are fused together, the needles are removed, resulting in elastic tissue based on the original cells and the collagen within. The Regenova bio 3D printer can automatically create a 3D cellular structure by inputting 3D data and cellular aggregate material. The resulting cellular structure spends several days or weeks maturing in a customized bioreactor, and comes to express its target strength and function. This technology can be used with various cell types, and is expected to bring breakthroughs in drug discovery research and regenerative medicine in a wide range of therapeutic areas. Cyfuse is involved in two on-going AMED projects. Phase I clinical research is on-going at Kyushu University hospital regarding OsteoChondral regeneration by implantation of 3D MSC constructs.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Bio 3D printer "Regenova"
|
Launched
|
The only commercially available scaffold-free bio 3D printer
|
Enter Chinese and European market. Find strategic partners for clinical development of the cellular applications.
|
Bio 3D printer "S-PIKE”
|
Launched
|
The only commercially available scaffold-free bio 3D printer
|
Enter Chinese and European market. Find strategic partners for clinical development of the cellular applications.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Jan, 2019 Started selling the Bio 3D printer "S-PIKE"
|
|
Alliance strategy
|
Cyfuse is looking for 1) collaboration partners (academia and business) to explore therapeutic applications using our 3D printing technology, 2) Licensees of 3D fabrication technology for commercial use.
|
|
|